Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute M Moll

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Biological Chemistry|January 31, 2006
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilizationYork Tomita, Natasha Marchenko, Susan Erster, et al.
Cell Death and Differentiation|November 12, 2016
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
Cancer Research|December 17, 2008
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrestChristian J Braun, Xin Zhang, Irina Savelyeva, et al.
Cell Death and Differentiation|September 5, 2018
Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
Nature Communications|June 30, 2021
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosityTamara Isermann, Özge Çiçek Şener, Adrian Stender, et al.
Cancer Research|April 3, 2004
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivoNicole Concin, Kirsten Becker, Neda Slade, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2007
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancerMirko Marabese, Sergio Marchini, Eleonora Marrazzo, et al.
Cancer Cell|August 15, 2018
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and InvasionRamona Schulz-Heddergott, Nadine Stark, Shelley J Edmunds, et al.
Molecular Cell|July 7, 2015
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMPXin Zhang, Ramona Schulz, Shelley Edmunds, et al.
Molecular Cell|January 11, 2016
MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53Magdalena Wienken, Antje Dickmanns, Alice Nemajerova, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Biological Chemistry|January 31, 2006
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilizationYork Tomita, Natasha Marchenko, Susan Erster, et al.
Cell Death and Differentiation|November 12, 2016
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
Cancer Research|December 17, 2008
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrestChristian J Braun, Xin Zhang, Irina Savelyeva, et al.
Cell Death and Differentiation|September 5, 2018
Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cellsDaniela Kramer, Nadine Stark, Ramona Schulz-Heddergott, et al.
Nature Communications|June 30, 2021
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosityTamara Isermann, Özge Çiçek Şener, Adrian Stender, et al.
Cancer Research|April 3, 2004
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivoNicole Concin, Kirsten Becker, Neda Slade, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2007
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancerMirko Marabese, Sergio Marchini, Eleonora Marrazzo, et al.
Cancer Cell|August 15, 2018
Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and InvasionRamona Schulz-Heddergott, Nadine Stark, Shelley J Edmunds, et al.
Molecular Cell|July 7, 2015
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMPXin Zhang, Ramona Schulz, Shelley Edmunds, et al.
Molecular Cell|January 11, 2016
MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53Magdalena Wienken, Antje Dickmanns, Alice Nemajerova, et al.
Pageof 10